Arsanis, Inc., a Vienna, Austria-based biotechnology start up dedicated to the development of anti-infective monoclonal antibody therapeutics, closed a $10m Series A financing.
Investors include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.
Managing Partners, Carl Gordon from OrbiMed Advisors, Terry McGuire from Polaris, and Mike Ross from SV Life Sciences, joined the founders on Arsanis’ Board of Directors.
The company intends to use the funds to advance several programs in the anti-microbial infectious disease area.
Founded in the fall of 2010 by CSO Dr. Eszter Nagy, Dr. Tillman Gerngross and Errik Anderson, Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments.
The company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients, or are associated with high mortality in spite of low rates of antibiotic resistance.